Warning: The NCBI web site requires JavaScript to function. more...
Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women.
Goss PE, Hadji P, Subar M, Abreu P, Thomsen T, Banke-Bochita J.
Breast Cancer Res. 2007;9(4):R52.
Related citations
Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230).
Eastell R, Hannon RA, Cuzick J, Dowsett M, Clack G, Adams JE; ATAC Trialists' group.
J Bone Miner Res. 2006 Aug;21(8):1215-23.
The effect of exemestane or tamoxifen on markers of bone turnover: results of a German sub-study of the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial.
Hadji P, Ziller M, Kieback DG, Menschik T, Kalder M, Kuck J, Hasenburg A.
Breast. 2009 Jun;18(3):159-64. Epub 2009 Apr 11.
The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'.
Atalay G, Dirix L, Biganzoli L, Beex L, Nooij M, Cameron D, Lohrisch C, Cufer T, Lobelle JP, Mattiaci MR, Piccart M, Paridaens R.
Ann Oncol. 2004 Feb;15(2):211-7.
Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane.
Gonnelli S, Cadirni A, Caffarelli C, Petrioli R, Montagnani A, Franci MB, Lucani B, Francini G, Nuti R.
Bone. 2007 Jan;40(1):205-10. Epub 2006 Aug 14.
A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer.
McCaig FM, Renshaw L, Williams L, Young O, Murray J, Macaskill EJ, McHugh M, Hannon R, Dixon JM.
Breast Cancer Res Treat. 2010 Feb;119(3):643-51.
Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.
Coleman RE, Banks LM, Girgis SI, Kilburn LS, Vrdoljak E, Fox J, Cawthorn SJ, Patel A, Snowdon CF, Hall E, Bliss JM, Coombes RC; Intergroup Exemestane Study group.
Lancet Oncol. 2007 Feb;8(2):119-27.
Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women.
McCloskey EV, Hannon RA, Lakner G, Fraser WD, Clack G, Miyamoto A, Finkelman RD, Eastell R.
Eur J Cancer. 2007 Nov;43(17):2523-31.
Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.
Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, Shenkier TN, Tozer RG, Palmer MJ, Shepherd LE, Liu S, Tu D, Goss PE.
J Clin Oncol. 2006 Aug 1;24(22):3629-35. Epub 2006 Jul 5.
Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer.
Lønning PE, Geisler J, Krag LE, Erikstein B, Bremnes Y, Hagen AI, Schlichting E, Lien EA, Ofjord ES, Paolini J, Polli A, Massimini G.
J Clin Oncol. 2005 Aug 1;23(22):5126-37. Epub 2005 Jun 27.
Effect of aromatase inhibition on bone metabolism in elderly hypogonadal men.
Leder BZ, Finkelstein JS.
Osteoporos Int. 2005 Dec;16(12):1487-94. Epub 2005 Apr 23.
Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study.
Geisler J, Haynes B, Anker G, Dowsett M, Lønning PE.
J Clin Oncol. 2002 Feb 1;20(3):751-7.
Effect of exemestane on tamoxifen pharmacokinetics in postmenopausal women treated for breast cancer.
Hutson PR, Love RR, Havighurst TC, Rogers E, Cleary JF.
Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8722-7.
The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study.
Markopoulos C, Polychronis A, Zobolas V, Xepapadakis G, Papadiamantis J, Koukouras D, Lappas H, Gogas H.
Breast Cancer Res Treat. 2005 Sep;93(1):61-6.
Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
Confavreux CB, Fontana A, Guastalla JP, Munoz F, Brun J, Delmas PD.
Bone. 2007 Sep;41(3):346-52. Epub 2007 Jun 16.
Bone safety of aromatase inhibitors versus tamoxifen.
Lønning PE.
Int J Gynecol Cancer. 2006;16 Suppl 2:518-20. Review.
Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review.
Eisen A, Trudeau M, Shelley W, Messersmith H, Pritchard KI.
Cancer Treat Rev. 2008 Apr;34(2):157-74. Epub 2007 Dec 31. Review.
Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M.
Clin Ther. 2007 Aug;29(8):1535-47. Review.
Comparative effects of anastrozole, tamoxifen alone and in combination on plasma lipids and bone-derived resorption during neoadjuvant therapy in the impact trial.
Banerjee S, Smith IE, Folkerd L, Iqbal J, Barker P, Dowsett M; IMPACT trialists.
Ann Oncol. 2005 Oct;16(10):1632-8. Epub 2005 Jul 19.
Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patients.
Carlini P, Michelotti A, Ferretti G, Ricci S, Giannarelli D, Pellegrini M, Cresti N, Di Cosimo S, Bria E, Papaldo P, Fabi A, Ruggeri EM, Milella M, Alimonti A, Salesi N, Cognetti F.
Cancer Invest. 2007 Mar;25(2):102-5.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on